Welcome to our dedicated page for Mural Oncology PLC SEC filings (Ticker: MURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical data tables, complex risk factors, and pages of cytokine biology make the Mural Oncology annual report 10-K simplified anything but simple. If you’re combing through nemvaleukin trial details or cash-runway notes, you know the frustration of translating biotech jargon into plain language.
That’s why Stock Titan pairs every Mural Oncology quarterly earnings report 10-Q filing, 8-K trial update, and Mural Oncology insider trading Form 4 transactions with AI-powered summaries. Our engine surfaces R&D spend trends, highlights FDA milestone disclosures, and flags liquidity warnings, giving you Mural Oncology SEC filings explained simply. Need to understand dilution risk from the latest offering? A click pulls up Mural Oncology 8-K material events explained with side-by-side comparisons to prior statements, while charted metrics turn dense numbers into clear visuals—a complete Mural Oncology earnings report filing analysis in minutes.
Real-time alerts mean you see Mural Oncology Form 4 insider transactions real-time, track each Mural Oncology executive stock transactions Form 4, and review the Mural Oncology proxy statement executive compensation without waiting for end-of-day feeds. Whether you’re hedge-fund analyst, sell-side researcher, or individual investor focused on understanding Mural Oncology SEC documents with AI, our coverage of every form—10-K, 10-Q, 8-K, S-3, plus exhibits—keeps you ahead of market-moving details. Complex biotech filings decoded, pipeline milestones tracked, decisions made faster.
Mural Oncology plc received a joint Schedule 13G/A from Armistice Capital, LLC and Steven Boyd reporting that the reporting persons do not beneficially own any ordinary shares of the issuer. The filing states zero shares owned and 0% of the class based on 17,324,359 shares outstanding as reported by the issuer.
The filing explains that Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and that Armistice Capital exercises voting and investment power over the Master Fund's securities. The Master Fund disclaims beneficial ownership due to its inability to vote or dispose of the securities under the investment management agreement. The Master Fund retains the right to receive dividends or sale proceeds.
Mural Oncology plc received an amended Schedule 13G filing from Solas Capital Management, LLC and Frederick Tucker Golden reporting that neither the adviser nor Mr. Golden beneficially own any ordinary shares of the company. The filing lists the issuer's Dublin address and the security CUSIP G63365103. Both reporting parties state 0 shares owned and 0.0% of the class, and clarify the adviser relationship to private funds while noting the funds disclaim beneficial ownership. Signatures by Frederick Tucker Golden certify the accuracy of the statement.
FAQ
What is the current stock price of Mural Oncology PLC (MURA)?
What is the market cap of Mural Oncology PLC (MURA)?
